ReviewJournal of inflammation research2026
Mesenchymal Stem Cell-Derived Exosomes: A Tool for Heart Failure Repair - From Molecular Mechanisms to Clinical Potential.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes are nanoscale vesicles abundantly distributed across biological fluids, serving as crucial mediators of intercellular communication by carrying bioactive molecules such as proteins, nucleic acids, and lipids. They exert pivotal functions in various physiological and pathological processes. Mesenchymal stem cell-derived exosomes (MSC-exos) exhibit low immunogenicity, minimal tumorigenic risk, abundant sources, and amenability to engineering modifications. Through the targeted delivery of bioactive molecules, MSC-exos exert multifaceted therapeutic effects in heart failure (HF) repair. They not only protect cardiomyocytes, thereby maintaining structural integrity, but also modulate immune and inflammatory responses, thereby improving the myocardial microenvironment. Additionally, they inhibit fibrosis, promote angiogenesis, and optimize myocardial metabolism, offering novel strategies and tools for the treatment of HF. This review aims to systematically elucidate the biological characteristics of MSC-exos, provide an in-depth analysis of their molecular mechanisms in HF therapy, summarize optimization strategies, and explore their potential in drug delivery and clinical applications. Furthermore, it discusses the challenges and future directions for clinical translation, thereby offering a comprehensive reference for both basic research and clinical practice regarding MSC-exos as a therapeutic tool for HF repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.